Relief Therapeutics Hldg Ag Stock Price, News & Analysis

Relief Therapeutics (OTCQB:RLFTY), a biopharmaceutical company focused on specialty and rare diseases, has moved up the publication date of its 2025 half-year report. The report will now be released on August 14, 2025, before market opening, instead of the originally planned date of August 27, 2025.

The earlier publication is attributed to the anticipated early completion of the report. The half-year report will contain interim financial statements and a shareholder update, which will be accessible on Relief's website upon release.

Relief Therapeutics (OTCQB:RLFTY) has announced a significant business combination with NeuroX, the successor company to MindMaze, through a binding term sheet. The transaction values Relief at CHF 100 million and NeuroX at CHF 1 billion. Post-merger, Relief shareholders will own approximately 9% of the combined entity, while NeuroX shareholders will hold 91%.

NeuroX, which recently acquired MindMaze's assets and operations, brings a clinically validated portfolio of AI-based digital neurotherapeutics for treating neurological diseases and brain disorders. The company has invested over $350 million in developing its platform, which combines software-delivered behavioral treatments with drugs, devices, and AI technology.

The transaction is expected to close in Q4 2025, subject to customary conditions including shareholder approvals, due diligence, and regulatory clearances.

Relief Therapeutics announced that the FDA did not grant Qualified Infectious Disease Product (QIDP) designation for RLF-TD011, their treatment for epidermolysis bullosa (EB). Despite this setback, the company's development strategy remains unchanged as RLF-TD011 maintains both Orphan Drug and Rare Pediatric Disease designations, offering potential seven-year market exclusivity in the US upon approval. The company holds a European patent for RLF-TD011 valid through 2040. Relief also reported a productive pre-IND meeting with the FDA regarding the development pathway for RLF-TD011, with written responses expected in the coming weeks.

Relief Therapeutics (RLFTY) held its Annual General Meeting on June 12, 2025, where shareholders approved all proposed resolutions with over 85% support. Key approvals included the 2024 annual report and financial statements, carrying forward the 2024 financial year net result, and granting discharge to the board and executive committee. The meeting re-elected Dr. Raghuram Selvaraju as chairman, along with board members Gregory Van Beek, Peter de Svastich, and Thomas Elzinga. Shareholders approved compensation packages for the board and executive committee, the 2024 compensation report, and re-appointed Thomas Hua as independent proxy and FORVIS MAZARS SA as statutory auditor.

Relief Therapeutics (RLFTY) has received FDA Rare Pediatric Disease (RPD) designation for RLF-TD011, targeting epidermolysis bullosa (EB), a rare genetic skin disorder. RLF-TD011 is a hypotonic acid-oxidizing solution with hypochlorous acid, designed to provide antimicrobial and anti-inflammatory benefits for wound healing. The treatment previously received Orphan Drug Designation and has shown promising clinical results in modulating wound microbiome. The RPD designation applies to diseases affecting fewer than 200,000 people under 18 in the US. If approved, Relief could receive a Priority Review Voucher (PRV), which can be sold - notably, a similar PRV for an EB treatment was recently sold for $155 million in May 2025.

Relief Therapeutics (RLFTY) has announced its upcoming 2025 Annual General Meeting (AGM) scheduled for June 12, 2025 at 10:00 a.m. CEST in Geneva, Switzerland. The AGM agenda includes standard items such as approval of the 2024 annual report and financial statements, earnings appropriation, board and executive committee discharge, and re-election of board members and chairman.

Additional agenda items cover re-election of nomination and compensation committee members, approval of maximum compensation for board and executive committee, a consultative vote on the 2024 compensation report, and re-election of independent voting rights representative and auditors. Formal convocation notice will be mailed to registered shareholders on May 21, 2025.

Relief Therapeutics (RLFTY) has released its 2024 Annual Report, highlighting operational achievements and pipeline progress. The company's chairman, Dr. Raghuram Selvaraju, emphasized their strengthened financial position and commitment to treating rare diseases.

Key developments include advancement of two core pipeline products:

• RLF-OD032: A next-generation liquid sapropterin formulation for phenylketonuria
• RLF-TD011: A proprietary hypochlorous acid solution for epidermolysis bullosa

The company anticipates significant clinical and regulatory milestones in 2025 as they continue to focus on delivering treatments for unmet medical needs.

Relief Therapeutics (RLFTY) has announced the termination of merger discussions with Renexxion, Inc. The talks, which began with a non-binding letter of intent in November 2024, were discontinued as key conditions for the transaction were not met within the required timeframe.

Despite the merger's discontinuation, Relief maintains a strong position with CHF 15 million in cash reserves and access to a CHF 50 million undrawn equity facility from their largest shareholder GEM. The company remains focused on advancing its core development programs and strategic objectives independently.

Relief will provide a detailed business update in their 2024 Annual Report, scheduled for release on April 10, 2025.

Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, RLFTY) announced that the European Patent Office (EPO) will grant a patent for its RLF-TD011 treatment on February 26, 2025. The patent, titled 'Therapeutic Uses of Oxidizing Hypotonic Acid Solutions,' will protect the company's proprietary hypochlorous acid solutions for treating epidermolysis bullosa (EB) wounds in European markets until 2040.

The treatment has already received orphan drug designation from the FDA, and Relief plans to seek qualified infectious disease product (QIDP) designation. The company recently reported positive results from its investigator-initiated clinical trial for RLF-TD011 and is preparing a pre-IND meeting package for FDA submission. Patent applications are also under review in other major markets, including the United States and China.